49873-11-2

Usage

Uses

Used in Pharmaceutical Research and Drug Development:
5-[(4-Benzyloxy)benzyl]-2,4-diaminopyrimidine serves as a valuable compound in pharmaceutical research and drug development due to its potential therapeutic properties. Its unique molecular structure allows it to engage with multiple biological targets, making it a candidate for further studies in medicinal chemistry aimed at discovering new treatments and therapies.
Used in Medicinal Chemistry Studies:
In the field of medicinal chemistry, 5-[(4-Benzyloxy)benzyl]-2,4-diaminopyrimidine is utilized as a subject of study for its molecular structure and properties. Researchers investigate its interactions with biological targets to explore its potential in the development of new pharmaceutical agents, contributing to the advancement of medicine and healthcare solutions.

InChI:InChI=1/C18H18N4O/c19-17-15(11-21-18(20)22-17)10-13-6-8-16(9-7-13)23-12-14-4-2-1-3-5-14/h1-9,11H,10,12H2,(H4,19,20,21,22)

Upstream product

• 30077-74-8 3-anilino-2-<4-(benzyloxy)benzyl>acrylonitrile 
• 50-01-1 guanidine hydrochloride 
• 100-39-0 benzyl bromide 
• 30077-67-9 2,4-diamino-5-(4-hydroxybenzyl)pyrimidine 
• 74189-56-3 4-(tetrahydropyran-2-yloxy)benzaldehyde 
• 123-08-0 4-hydroxy-benzaldehyde 
• 650606-19-2 (E)-2-(ethoxymethyl)-3-[4-(tetrahydro-2-pyranyloxy)phenyl]-2-propenenitrile 
• 650606-20-5 5-[4-(tetrahydro-pyran-2-yloxy)-benzyl]-pyrimidine-2,4-diamine 
• 4397-53-9 p-benzyloxybenzaldehyde 
• 116168-96-8 (Z)-2-(4-Benzyloxy-benzyl)-3-morpholin-4-yl-acrylonitrile 

Downstream Products

• 30077-67-9 2,4-diamino-5-(4-hydroxybenzyl)pyrimidine 

Relevant academic research and scientific papers

2,4-Diaminopyrimidines as inhibitors of leishmanial and trypanosomal dihydrofolate reductase

This paper describes the synthesis of 4′-substituted and 3′,4′-disubstituted 5-benzyl-2,4-diaminopyrimidines as selective inhibitors of leishmanial and trypanosomal dihydrofolate reductase. Compounds were then assayed against the recombinant parasite and human enzymes. Some of the compounds showed good activity. They were also tested against the intact parasites using in vitro assays. Good activity was found against Trypanosoma cruzi, moderate activity against Trypanosoma brucei and Leishmania donovani. Molecular modeling was undertaken to explain the results. The leishmanial enzyme was found to have a more extensive lipophilic binding region in the active site than the human enzyme. Compounds which bound within the pocket showed the highest selectivity.

Synthesis and antimycobacterial effects of some lipophilic substituted 2,4-diamino-5-benzylpyrimidines

2,4-Diamino-5-benzylpyrimidines 1-23 with lipophilic substitution in the benzylic moiety were synthesized by the morpholino-anilino-procedure. Their effects against various mycobacteria were verified by MIC (minimum inhibitory concentration) in whole cells and I50-measurements in whole cell and cell-free systems. Especially the substances 7-12 are strong inhibitors of some atypical mycobacterial strains which are sometimes associated with tuberculosis in the elderly and with AIDS. They might be promising candidates for therapy.